•  Summary 
  •  
  •  Actions 
  •  
  •  Committee Votes 
  •  
  •  Floor Votes 
  •  
  •  Memo 
  •  
  •  Text 
  •  
  •  LFIN 
  •  
  •  Chamber Video/Transcript 

A03833 Summary:

BILL NOA03833
 
SAME ASNo Same As
 
SPONSORWeprin
 
COSPNSR
 
MLTSPNSR
 
Amd §§3216, 3221 & 4303, Ins L; amd §365-a, Soc Serv L
 
Requires insurance companies, medical expense indemnity corporations, hospital service corporations, health service corporations and medical assistance programs to provide coverage for prescribed antiviral therapeutics approved by the food and drug administration for the treatment of COVID-19 at no cost to the patient.
Go to top

A03833 Text:



 
                STATE OF NEW YORK
        ________________________________________________________________________
 
                                          3833
 
                               2025-2026 Regular Sessions
 
                   IN ASSEMBLY
 
                                    January 30, 2025
                                       ___________
 
        Introduced by M. of A. WEPRIN -- read once and referred to the Committee
          on Insurance
 
        AN  ACT  to  amend  the  insurance  law  and the social services law, in
          relation to capping cost sharing for antiviral COVID-19 therapeutics
 
          The People of the State of New York, represented in Senate and  Assem-
        bly, do enact as follows:
 
     1    Section  1.    Subsection  (i) of section 3216 of the insurance law is
     2  amended by adding a new paragraph 40 to read as follows:
     3    (40) (A) Every policy that provides coverage  for  prescription  drugs
     4  shall  provide  coverage  for antiviral therapeutics approved or granted
     5  emergency use authorization by the food and drug administration for  the
     6  treatment of COVID-19 when prescribed by a licensed health care provider
     7  legally authorized to prescribe under title eight of the education law.
     8    (B)  Coverage  under  this  paragraph  shall  not be subject to annual
     9  deductibles or coinsurance, provided, however, that an  insured  who  is
    10  eligible  for and able to obtain prescribed antiviral therapeutics at no
    11  cost or reduced cost under a manufacturer or government program  may  be
    12  required  to use such program before using coverage required pursuant to
    13  this paragraph.
    14    § 2. Subsection (k) of section 3221 of the insurance law is amended by
    15  adding a new paragraph 24 to read as follows:
    16    (24) (A) Every group or blanket policy delivered or issued for  deliv-
    17  ery  in  this  state that provides coverage for prescription drugs shall
    18  provide coverage for antiviral therapeutics approved or granted emergen-
    19  cy use authorization by the food and drug administration for the  treat-
    20  ment  of  COVID-19  when  prescribed  by a licensed health care provider
    21  legally authorized to prescribe under title eight of the education law.
    22    (B) Coverage under this paragraph  shall  not  be  subject  to  annual
    23  deductibles  or  coinsurance,  provided, however, that an insured who is
    24  eligible for and able to obtain prescribed antiviral therapeutics at  no
    25  cost  or  reduced cost under a manufacturer or government program may be
 
         EXPLANATION--Matter in italics (underscored) is new; matter in brackets
                              [ ] is old law to be omitted.
                                                                   LBD07443-01-5

        A. 3833                             2
 
     1  required to use such program before using coverage required pursuant  to
     2  this paragraph.
     3    §  3.  Section  4303  of  the insurance law is amended by adding a new
     4  subsection (ww) to read as follows:
     5    (ww) (1) Every contract issued by a medical expense  indemnity  corpo-
     6  ration,  a hospital service corporation, or a health service corporation
     7  that provides coverage for prescription drugs shall provide coverage for
     8  antiviral therapeutics approved or granted emergency  use  authorization
     9  by  the  food and drug administration for the treatment of COVID-19 when
    10  prescribed by a licensed health  care  provider  legally  authorized  to
    11  prescribe under title eight of the education law.
    12    (2)  Coverage  under  this  subsection  shall not be subject to annual
    13  deductibles or coinsurance, provided, however, that an  insured  who  is
    14  eligible  for and able to obtain prescribed antiviral therapeutics at no
    15  cost or reduced cost under a manufacturer or government program  may  be
    16  required  to use such program before using coverage required pursuant to
    17  this subsection.
    18    § 4. Subdivision 2 of section 365-a of  the  social  services  law  is
    19  amended by adding a new paragraph (nn) to read as follows:
    20    (nn)  (i)  antiviral  therapeutics  approved  or granted emergency use
    21  authorization by the food and drug administration for the  treatment  of
    22  COVID-19  when  prescribed  by  a  licensed health care provider legally
    23  authorized to prescribe under title eight of the education law.
    24    (ii) coverage under this paragraph shall be provided at no cost to the
    25  insured, provided, however, that an insured who is eligible for and able
    26  to obtain prescribed antiviral therapeutics at no cost or  reduced  cost
    27  under  a  manufacturer or government program may be required to use such
    28  program before using coverage required pursuant to this paragraph.
    29    § 5. This act shall take effect on  the  first  day  of  January  next
    30  succeeding  the date on which it shall have become a law and shall apply
    31  to all policies and contracts issued,  renewed,  modified,  altered,  or
    32  amended on or after such date.
Go to top